

Journal Pre-proof



ROLE OF RISK SCORING SYSTEMS IN PREDICTING LIFE EXPECTANCY AFTER CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS.

Daniele Bissacco, MD, Chiara Malloggi, PhD, Maurizio Domanin, MD, Laura Cortesi, BSc, Luigia Scudeller, MD MScEpid, Jason Mognarelli, MD, Tiziano Porretta, MD, Emidio Costantini, MD, Vincenzo Silani, MD, Gianfranco Parati, MD, Santi Trimarchi, MD PhD, Renato Casana, MD

PII: S0741-5214(21)02169-8

DOI: <https://doi.org/10.1016/j.jvs.2021.08.099>

Reference: YMVA 12237

To appear in: *Journal of Vascular Surgery*

Received Date: 24 February 2021

Accepted Date: 25 August 2021

Please cite this article as: Bissacco D, Malloggi C, Domanin M, Cortesi L, Scudeller L, Mognarelli J, Porretta T, Costantini E, Silani V, Parati G, Trimarchi S, Casana R, ROLE OF RISK SCORING SYSTEMS IN PREDICTING LIFE EXPECTANCY AFTER CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS., *Journal of Vascular Surgery* (2021), doi: <https://doi.org/10.1016/j.jvs.2021.08.099>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2021 Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.

1 **ROLE OF RISK SCORING SYSTEMS IN PREDICTING LIFE EXPECTANCY AFTER**
2 **CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS.**

3 **R2WC: 242/3690**

4

5 Daniele Bissacco, MD ¹, Chiara Malloggi, PhD ², Maurizio Domanin, MD ^{1,3}, Laura Cortesi,
6 BSc ⁴, Luigia Scudeller, MD MScEpid ⁴, Jason Mognarelli, MD ⁵, Tiziano Porretta, MD ⁶,
7 Emidio Costantini, MD ⁵, Vincenzo Silani, MD ^{7,8}, Gianfranco Parati, MD ^{9,10}, Santi Trimarchi,
8 MD PhD ^{1,3}, Renato Casana, MD ^{2,11}

9

10 ¹ Unit of Vascular Surgery, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

11 ² Laboratory of Research in Vascular Surgery, IRCCS Istituto Auxologico Italiano, Milan, Italy

12 ³ Department of Clinical and Community Sciences, University of Milan, Milan, Italy

13 ⁴ Department of Clinical Epidemiology and Biostatistics, IRCCS Ca' Granda Ospedale Maggiore
14 Policlinico, Milan, Italy

15 ⁵ Vascular Surgery Unit, ASST della Valle Olona, Busto Arsizio (VA), Italy

16 ⁶ Vascular Surgery Unit, ASST Fatebenefratelli-Sacco, Milan, Italy

17 ⁷ Neurology-Stroke and Neuroscience Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy

18 ⁸ Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

19 ⁹ Cardiovascular, Neural and Metabolic Sciences Unit, IRCCS Istituto Auxologico Italiano,
20 Milan, Italy

21 ¹⁰ Department of Medicine and Surgery, Università di Milano-Bicocca, Monza, Italy.

22 ¹¹ Unit of Vascular Surgery, IRCCS Istituto Auxologico Italiano, Milan, Italy

23

1 **CORRESPONDING AUTHOR:**

2 Daniele Bissacco, MD

3 Vascular Surgery Unit

4 IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

5 via Francesco Sforza, 28 - 20122 Milan, Italy

6 email: danielebissacomd@gmail.com

7 phone: +39 0255035658

8 fax: +39 0255035658

9

10 **KEYWORDS:** carotid endarterectomy; asymptomatic carotid stenosis; survival analysis; risk
11 scoring system; stroke

12

13 **SUBJECT TERMS:** carotid disease; stenosis; mortality/survival

14

15 **ARTICLE HIGHLIGHTS**

16 **Type of Research:** Retrospective multicenter study.

17 **Key Findings:** For 825 asymptomatic carotid endarterectomy candidate patients, six published
18 risk scoring systems designed to predict postoperative life-expectancy were used to predict 3-
19 year and 5-year mortality rates, resulting in high specificity (82.4% and 82.5%, respectively) and
20 suboptimal accuracy (highest Harrell's value: 0.646 and 0.609 for 3-year and 5-year mortality,
21 respectively).

1 **Take home Message:** Risk scoring systems may be used for asymptomatic patients before
2 carotid endarterectomy to evaluate long-term surgery efficacy, bearing in mind those results
3 should be integrated with other preoperative prognostic tools.

4

5 **SUMMARY FOR TABLE OF CONTENTS**

6 A real-world validation of six published risk score systems to predict survival rate after carotid
7 endarterectomy in asymptomatic patients demonstrated acceptable diagnostic validity and
8 mortality rate estimation in only two. Although this kind of analysis may help clinicians assess
9 asymptomatic patients' life expectancy and justify surgery in term of postoperative long-term
10 benefit, other available preoperative parameters should be taken into account.

11

12 **ABSTRACT**

13 **OBJECTIVE:** The aim of this study is to compare and to test the performance of all available
14 risk scoring systems (RSSs) designed to predict long-term survival rate in asymptomatic
15 candidate patients for carotid endarterectomy (CEA) for significant carotid artery stenosis.

16 **METHODS:** Data on asymptomatic patients who underwent CEA in three high-volume centers
17 were prospectively recorded. Through literature research using PRISMA recommendations, six
18 RSSs were identified for the intent of the study. Primary endpoints were 3- and 5-year survival
19 rate after CEA. All items used as variables to compose multiple RSSs were applied to every
20 patient in the study population. The 3-year and 5-year mortality prediction rates for each score
21 were assessed by sensitivity, specificity, predictive negative and positive value calculation, as
22 well as univariable Cox proportional hazard models with the Harrell's C index.

1 RESULTS: During the study period, 825 CEAs in 825 asymptomatic patients were analyzed. All
2 items used in RSSs were available in the dataset, with some concerns regarding their definition
3 and application among RSSs. The 3-year and 5-year survival rates of the study cohort were
4 94.5% and 90.3%, respectively. Among the six RSSs analyzed, no RSS demonstrated optimal
5 results in terms of mortality rate prediction accuracy, although some scores had good diagnostic
6 and risk of death precision.

7 CONCLUSION: RSSs, when used alone, fail to optimally detect postoperative life-expectancy in
8 asymptomatic CEA patient candidates. Further prospective controlled studies are needed to
9 compose and validate RSSs with better calibration to predict outcomes.

10

11 INTRODUCTION

12 Carotid endarterectomy (CEA) remains the most commonly used procedure worldwide to
13 prevent or minimize the recurrence of stroke due to carotid artery stenosis, in both asymptomatic
14 and symptomatic patients. Despite a multitude of publications and guidelines, in contrast with
15 indications for CEA in symptomatic patients, the role of surgery to treat asymptomatic patients is
16 still debated.¹⁻⁵ This is because suggesting routine prophylactic CEA remains subject to several
17 concerns. Most important, improvements in pre- and post-procedural best medical therapy
18 (BMT) over the past decades have enabled a progressive decline in the annual risk of late stroke,
19 a decline particularly significant in some asymptomatic patients' low risk subgroups, such as
20 patients without relevant comorbidities, plaque-related risk factors and normal cerebrovascular
21 imaging findings.^{6,7} Furthermore, although the majority of centers reach a perioperative
22 complication rate <3% during CEA, few studies have tried to assess life expectancy in

1 asymptomatic patients, and thus there are no unequivocal and clear recommendations about this
2 topic.

3 In this context, risk scoring systems (RSSs) have been proposed to best identify which patients
4 with asymptomatic carotid artery stenosis could benefit from CEA or if poor life expectancy may
5 contraindicate surgery. These tools should permit, in a rapid and easy way, to preoperatively
6 stratify long-term mortality risk in candidates for CEA and to predict the benefits of surgical
7 treatment. Although several RSSs are proposed in the literature, no robust and external
8 validations are provided in the majority of cases.⁸

9 The aim of this study is to validate and test the accuracy of RSSs designed to predict long-term
10 mortality rate (3-year and 5-year) after CEA in asymptomatic patients, using a real-world,
11 multicenter population as the validation cohort.

12

13 **MATERIALS AND METHODS**

14 This analysis was conducted according to the Declaration of Helsinki of the World Medical
15 Association. All patients provided written informed consent before participation. The study was
16 approved by the local ethics committee of the promoting center (VASCOR-AUX project, nr.
17 2020_06_16_10, approved on June 30, 2020) and the research ethics committee of each
18 participating hospital.

19

20 **SCORING SYSTEMS SEARCH STRATEGY**

21 First, in order to obtain and analyze all RSSs published in the literature, a research strategy
22 similar to that used by Bissacco and coworkers was adopted.⁸ In brief, according to
23 recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses

1 (PRISMA) guidelines⁹, the most important medical on-line databases (PubMed, EMBASE and
2 The Cochrane Library) were interrogated to acquire the first article cluster. In this case, in
3 contrast to a prior publications⁸, the time range was set from January 1, 1990, to December 31,
4 2019. Further search strategy details are described in Supplementary Material, section S1.
5 Potential useful references to eligible studies could also be included in the selected article
6 cluster. Only RSSs designed for long-term (at least 3 years) mortality assessment in patients
7 undergoing CEA for asymptomatic carotid artery stenosis were included. RSSs predicting only
8 stroke, cardiovascular complications, or combined outcomes (e.g., stroke/death,
9 stroke/myocardial infarction [MI]/death) were excluded if it was not possible to clearly identify
10 the long-term mortality rate. Scores derived from mixed (asymptomatic and symptomatic)
11 population were also included, but only if the number of asymptomatic patients in the study
12 population was greater than those symptomatic. Potentially useful titles were reviewed
13 independently by two Authors (DB and CM). If no acceptable consensus on article eligibility
14 was reached, a third investigator (ST) was consulted. Selected papers were then analyzed in
15 terms of items used and their “weight” into the score (points assignment). All items of all
16 selected scores were inserted into a database designed *ad hoc* for study population analysis.

17

18 STUDY POPULATION

19 Data about all consecutive patients who underwent CEA for asymptomatic carotid artery stenosis
20 at three high-volume centers for vascular and endovascular surgery (>50 CEA/year) were
21 initially included: Istituto Auxologico Italiano from January 1, 2008 to December 31, 2017;
22 Ospedale di Circolo di Busto Arsizio (ASST della Valle Olona) from January 1, 2014 to June 30,

1 2015; Ospedale Luigi Sacco (ASST Fatebenefratelli-Sacco) from January 1, 2008 to December
2 31, 2016.

3 Asymptomatic status was assessed by absence of stroke / transient ischemic attack (TIA) for at
4 least six months before CEA. Patients already treated for ipsilateral and/or contralateral carotid
5 artery stenosis were excluded.

6 All data were prospectively recorded and retrospectively analyzed. Two Authors (DB and CM)
7 provided and sent an *ad hoc* dataset sheet (Excel, Microsoft Corp., Redmond, WA) to each
8 center.

9 Although among RSSs item definitions were quite heterogeneous, consensus was achieved
10 among participants, before the beginning of dataset compilation. In particular, in order to define
11 each score item univocally, three Authors, one for each participating center (DB, CM and JM),
12 were interrogated. Authors were asked to rate each item in terms of definition clarity provided by
13 the paper in which the item was used, and applicability in our population. Applicability was
14 defined as the effective and practical use of a specific item into the real-world, non-selected
15 patients' cohort.

16 A 5-level Likert Scale¹⁰ was used to rate Author response for each item (see Supplementary
17 Material, S2 section, Figure 1S). Furthermore, comments were provided to better assess
18 limitations in reproducibility of a specific item (see Supplementary Material, S3 section).

19 After single-center dataset completion, all data were pooled into a unique database. Only two
20 Authors (DB and LS) could access and analyze the multicenter combined database.

21 Despite some specific centers' and/or surgeons' preferences, all patients were managed and
22 treated according to the latest recommendations provided by the Italian Society of Vascular and
23 Endovascular Surgery (SICVE)¹¹ and the European Society for Vascular Surgery (ESVS)¹

1 guidelines, in force during the enrollment periods. In particular, asymptomatic carotid stenosis
2 was assessed by color Doppler ultrasound scan (CDUS) analysis performed by at least two
3 skilled operators or confirmed by computed tomography angiography (CTA). A significant
4 stenosis was defined as 60-99% (using NASCET measurement method) and/or with a peak
5 systolic velocity (PSV) ≥ 230 cm/sec, a PSV_{ICA}/PSV_{CCA} ratio ≥ 4 or a $PSV_{ICA}/$ end diastolic
6 velocity $(EDV)_{CCA} > 10$ (where ICA and CCA indicate internal and common carotid artery,
7 respectively). Perioperative BMT was adopted before and after CEA. Surgery was performed
8 under local or general anesthesia. In the latter case, continuous electroencephalogram (EEG)
9 analysis was used. Shunt was used only in case of intraoperative EEG changes or clinical signs
10 of hemispheric ischemia. Dacron or bovine pericardium graft angioplasty, primary closure or
11 eversion endarterectomy were performed depending on carotid anatomy and personal preference.
12 Postoperative follow-up evaluations were guaranteed through clinical and CDUS examination.
13 Survival rate was assessed through clinical visit or with telephone calls. Data about
14 demographics, comorbidities, preoperative drug intake, procedural and postprocedural outcomes
15 were noted, referring to items used in selected RSSs.

16

17 RSSs SELECTION

18 Figure 1 shows the selection workflow and results of RSS research, according to methodology in
19 the PRISMA statement. After systematic selection and application of inclusion/exclusion criteria,
20 six RSSs were found and analyzed in depth (Tables Is and IIs, Supplementary Material, section
21 S2).¹²⁻¹⁷ Detailed description of each score in terms of development, calibration, advantage and
22 limits is available in a previous publication.⁸ In establishing the Keyhani score to use, the 4C
23 model was preferred over the Carotid Mortality Index (CMI), due to its better results in terms of

1 feasibility and calibration.¹⁷ Fourteen items were derived from the six selected scoring systems
2 (Table I). All items were present in the whole population dataset of this study, after the
3 abovementioned meeting to reach unanimous agreement about the definition of items used for
4 scoring. All selected items were relative to preoperative conditions. Specifically, two items were
5 related to demographic characteristics (age and sex), eight to comorbidities (smoking history,
6 diabetes mellitus [DM], chronic obstructive pulmonary disease [COPD], heart disease history,
7 renal function, any cancer in the past 5 years, neck radiation, congestive heart failure [CHF]),
8 and two to medical therapy (taking statins and antiplatelet or not). Two items were about carotid-
9 related features (stenosis grade and contralateral carotid stenosis [CCS]). Age, sex, smoking
10 history, DM, COPD, heart disease history and renal function were the items most frequently used
11 (5 scores out of 6). According to the Authors Likert Scale completion (Table IIIs, Supplementary
12 Material, section S4), average applicability of items in our population was acceptable (median
13 4.7, IQR 3.5-5.0), although two items were judged quite heterogeneous among RSSs and with
14 low applicability (renal function and CHF). The item “smoke” was defined as “past or current
15 smoking”, because of the definition adopted by the only RSSs using it among score items.¹⁵

16

17 PRIMARY AND SECONDARY OUTCOMES

18 Primary endpoints were 3-year and 5-year survival rates postoperatively. Each selected RSS was
19 tested on the study population, to assess accuracy in terms of 3-year and 5-year risk of death after
20 CEA, through an external validation analysis.

21

22 STATISTICAL ANALYSIS

1 Descriptive statistics were produced for the demographic, clinical and laboratory characteristics
2 of cases. Mean and standard deviation (SD) are presented for normally distributed variables,
3 median and interquartile range (IQR) for non-normally distributed variables, and number and
4 percentages for categorical variables. Whenever relevant, 95% confidence intervals (95% CI)
5 were calculated.

6 To assess the external validity of the proposed scores, we applied survival analysis techniques as
7 in the original studies from which the RSS methodologies were derived.

8 The event of interest was death, and patients still alive at last follow-up were censored. The time
9 for analysis was the number of months from CEA surgery to last instance of follow-up data.

10 Univariable Cox proportional hazard models were fitted, with each score as the only independent
11 variable. Survival curves were plotted using the Kaplan-Meier method, including the number of
12 patients at risk, cumulative number of events and the number of patients censored at each time
13 point (See Supplementary Material, Section S5, Figure 2S), with all subjects in the cohort
14 considered at the date of last follow up. We assessed the discriminative power of each score to
15 predict overall long-term mortality rate by calculating Harrell's C index (which corresponds to
16 the Receiver Operating Characteristic [ROC] curve for survival models). Additionally,
17 sensitivity (Se), specificity (Sp) and positive/negative predictive values (PPV and NPV,
18 respectively) for death at 3 and 5 years from CEA of each score (in case of scores with more than
19 two risk classes, the optimal cut-off was chosen) were estimated.

20 All analyses were done using Stata 16 (Stata Corporation, College Station, TX, USA). To
21 indicate statistical significance of results, a two-sided p value ≤ 0.05 was considered as cut-off
22 value. A Harrell's C value (HCv) ≥ 0.7 was considered as the cut-off to discriminate between an
23 optimal, suboptimal (0.69 – 0.60) or insufficient (0.59 – 0.50) prediction model.

1 RESULTS

2 STUDY POPULATION

3 During the study period, 1145 CEAs in 985 patients were performed. Based on the inclusion
4 criteria, which excluded patients with previous contralateral or ipsilateral carotid intervention,
5 825 CEAs in 825 asymptomatic patients were screened. All patients were included in the
6 analysis. Two hundred and eighty-six (34.7%) patients were enrolled from Istituto Auxologico
7 Italiano, 172 (20.8%) from Ospedale di Circolo di Busto Arsizio and 367 (44.5%) from Ospedale
8 Luigi Sacco. Demographic preoperative and intraoperative data are reported in Table II. More
9 than half of the patients were male (528 patients, 64.0%). Six hundred and eighty-eight (83.4%)
10 were on antiplatelet drugs and 602 patients (72.9%) were on statin therapy at admission. General
11 anesthesia under EEG was proposed in 265 patients (32.1%). The eversion technique was used in
12 the majority of cases (723 patients [87.6%]). Only one patient died within 30 days of CEA,
13 resulting in a 99.8% survival rate. Survival rates at 3 and 5 years from surgery were 94.5% and
14 90.3%, respectively (see also Supplementary Material, S5 section, Figure 2S).

16 RSS PERFORMANCE ON THE STUDY POPULATION

17 Three-year performance

18 Three-year results are summarized in Table III. As noted, all RSSs showed low Se and PPV; on
19 the contrary Sp and NPV are acceptable, although not optimal except in one case.¹⁷ Regarding
20 accuracy in detected 3-year death patients, three scores^{12,14,17} demonstrated significant risk class
21 discrimination, with an increasing risk of postoperative death among classes. In particular, the
22 highest HCv was detected in the Keyhani score (0.646, p=.002).¹⁷ In the same score, classes 1
23 and 2 increase the mortality rate at this follow-up time (HR 2.28, IC95% 1.06 – 4.90 and HR

1 5.58, IC95% 2.35 – 13.25, respectively). Unfortunately, no patients allocated in class 3-4 were
2 found in the study population. Moreover, class >2 in the Alcocer score ¹² triples the 3-year
3 mortality risk (OR 3.16, IC95% 1.72 – 5.81), with acceptable HCv (0.638, p<.001). Finally,
4 although the Wallaert score ¹⁴ demonstrated an acceptable HCv value (0.614, p=.034), it was
5 only able to discriminate patients with an augmented 3-year mortality risk for the “high risk”
6 class (HR 4.94, IC95% 1.12 – 21.75).

7 In summary, none of the selected scores reach optimal Harrell’s C values, with three scores
8 ranking suboptimal ^{12,14,17} and three generating insufficient values. ^{13,15,16}

9 Five-year performance

10 Table IV describes RSSs tested for 5-year mortality rate. In this case, results are similar to those
11 mentioned for the 3-year accuracy. At this follow-up time, RSSs demonstrated higher values of
12 Se and PPV when compared to 3-year results. The Keyhani score (HCv 0.609, p<.001) ¹⁷ showed
13 significant discrimination only in cases of “class 2” patients (HR 3.53, IC95% 1.92 – 6.51). In
14 this case, class >2 in the Alcocer score (HCv 0.595, p<.001) ¹² doubled the 5-year mortality risk
15 (OR 2.06, IC95% 1.33 – 3.20). The Wallaert score ¹⁴ showed a similar limitation to that noted at
16 3-year follow-up time, having an acceptable HCv value (0.599, p=.021), but significant
17 discrimination only for the “high risk” class (HR 3.05, IC95% 1.24 – 7.50).

18 In conclusion, only one ¹² score reached significant HR_{IC} for each risk class. Harrel’s C values
19 are all under suboptimal cut-off, except in one case. ¹⁷

20

21 **DISCUSSION**

22 This study provides an analysis of the six main RSSs found in the literature designed to predict
23 long-term postoperative mortality rate in asymptomatic patients candidate to CEA, to quantify

1 the applicability for everyday-practice and to validate them as predictive tools. The results
2 obtained highlight some important considerations:

- 3 - RSSs may be used in clinical practice, despite the fact that for some score items (renal function
4 and cardiac patient's history, in particular) applicability in a real context remains quite difficult,
5 due to heterogeneity in definitions among derivation studies.
- 6 - For both 3-year and 5-year postoperative life expectancy prediction, RSSs composed of few
7 risk classes (from 2 to 4) seem to be good prognostic tools.
- 8 - Suboptimal HCv, high Sp and low Se values indicate that RSSs may be used to validate the
9 advantage of CEA particularly in low-risk class patients.
- 10 - On the contrary, quantification of the postoperative mortality risk – through HR calculation – is
11 significant only for high-risk class patients.
- 12 - Only two RSSs^{12,17} have an acceptable risk class discrimination, demonstrating significant HR
13 and HR_{CI} for each class, for both 3-year and 5-year results.

14 Proposing prophylactic CEA or stenting for all asymptomatic patients with significant carotid
15 artery stenosis remains a topic of debate, despite several publications emphasizing that only
16 high-risk patients should undergo intervention.^{18,19} Many plaque, stenosis and patient-related
17 features have been described to discriminate in what kind of patient CEA may positively impact
18 cerebrovascular outcomes.⁶ A recent population-based cohort study and associated systematic
19 review and meta-analysis provided by the Oxford Vascular Study highlighted the controversial
20 role of the carotid stenosis grade cut-offs used to stratify and indicate intervention.²⁰ The
21 Authors found that stroke risk was higher in patients with 70-99% stenosis than in those with 50-
22 69% stenosis, suggesting that the benefit of CEA might be underestimated in patients with severe
23 stenosis and overestimated in those with moderate stenosis. This study seems to demonstrate that

1 even well-established parameters used to indicate intervention in carotid disease may be
2 questioned or reinterpreted in the light of new evidence. The identification and/or selection of
3 appropriate patient subgroups is urgently needed ^{21,22} to avoid unnecessary procedures.
4 Furthermore, the definition of “high risk patient” should be better assessed. In fact, it is first
5 necessary to differentiate between “*high risk* carotid plaque”, “*high risk* carotid stenosis” and
6 “*high risk* patient”. These three features must be weighed and balanced to provide the best
7 therapeutic choice for each case. Moreover, patient preoperative prognostic assessment may be
8 further distinguished into two aspects: *high risk* in terms of the perioperative period or *high risk*
9 in terms of the long-term (> 30 days) postoperative period.
10 Despite these discrepancies, several studies were published to maximize the adherence to
11 guideline recommendations (perioperative risk <3% and patient’s life expectancy >3-5 years)
12 and to improve patient outcomes.
13 To evaluate the postoperative mortality risk, Volkers et al. tried to predict short- and long-term
14 outcomes after carotid artery stenting or CEA in a cohort of symptomatic patients, using
15 currently available RSSs. ²³ The analysis, conducted on 2184 carotid artery stenting procedures
16 and 2261 CEAs, demonstrated low reliability in detecting patients at higher risk of short- and
17 long-term postoperative complications. Despite the high quality of this work, in symptomatic
18 patients the postoperative long-term life expectancy assessment is unnecessary in the majority of
19 cases, because in these patients CEA or stenting is strictly indicated to avoid recurrent stroke,
20 which happened within the first two weeks from symptom onset. ^{7,24}
21 Conversely, the CEA-8 risk score was proposed by Cavillo-King and coworkers to create a
22 multivariate model of risk of death and/or stroke within 30 days of CEA for asymptomatic
23 disease in 6553 Medicare beneficiaries. ²⁵ Female sex, nonwhite race, severe disability,

1 congestive heart failure, coronary artery disease, valvular heart disease, a distant history of stroke
2 or transient ischemic attack, and a non-operated stenosis $\geq 50\%$ were the items used to score each
3 patient. In the case of five or more risk factors, the combined rate of postoperative death or
4 stroke was 9.6%, while it was 0.6% with fewer than five risk factors. Although in some cases the
5 rate of postoperative complications exceeds 3%, several recent large scale controlled and non-
6 controlled studies have described a lower incidence of perioperative stroke and death, decreasing
7 the usefulness of short-term RSSs.²⁶⁻²⁸ Our analysis confirms this trend.

8 Finally, DeMartino et al. published in 2017 an RSS to predict postoperative stroke and 1-year
9 mortality rates in Vascular Quality Initiative (VQI) patients.²⁹ Unfortunately this score was not
10 included in our analysis due to the less than three-year follow-up. Sixteen items derived from ten
11 clinical, instrumental and blood sample parameters were evaluated to compose a triple-class
12 score with good calibration (AUC 0.750 for 1-year mortality validation). Further long-term
13 analysis should be performed to increase clinical usefulness of this encouraging RSS.

14 In our population, results obtained by the 3-year and 5-year prediction model reveal that only
15 two RSSs (Alcocer and Keyhani scores)^{12,17} seem able to predict postoperative mortality rate
16 according to each class risk stratification. This probably due to the presence of the following
17 RSS characteristics: 1. the large number of patients enrolled in the Keyhani score to obtain
18 robust results; 2. the use of few items in the 4C model used to compose the Keyhani score; 3.
19 simple risk stratification, with only 2 classes in the Alcocer score; and 4. a short range between
20 the lowest and the highest score obtainable in a single patient (10 in the Alcocer score, 4 in the
21 4C Keyhani score).

22 In our experience, these RSS characteristics lead to very simple models with low patient score
23 dispersion, obtaining good results.

1 Despite this, the use and validation of RSSs have some limitations. First, heterogeneity in the
2 definition of items may introduce misunderstandings and may reduce RSS applicability. For this
3 reason, the use of a Likert scale to obtain consensus among study participants, before data
4 acquisition, seems to be a valid tool to reach uniformity in patients' scoring and class allocation.
5 Second, some items were poorly represented in our study population (e.g., neck radiation,
6 congestive heart failure NYHA class III or IV) probably because in the case of these specific
7 comorbidities, indication for CEA is avoided or postponed. This could be associated with a
8 suboptimal patient class stratification in some RSSs. Third, results indicate that RSSs are valid
9 tools particularly for low-risk patients, despite the observation that in selected RSSs^{12,17} as the
10 risk class increases, the 3- and 5-year mortality rate increases. Fourth, the lack of data on
11 postoperative medical therapies such as antiplatelet or statin therapy, may modify postoperative
12 outcomes and the role of preoperative RSSs. Finally, RSSs do not provide any information
13 regarding plaque- or stenosis-related prognostic risk factors, although one RSS uses ipsilateral
14 stenosis grade¹⁵ and one uses contralateral stenosis grade.¹⁴ This omission may make an RSS
15 easier to use – being composed only of clinical and laboratory items – but also leads to a partial
16 risk assessment for the patient. Other well-known^{6,30} and some newly developed^{31,32} parameters
17 should be taken into account to better estimate short and long-term outcomes in these patients.
18 Moreover, this study has some limitations. Retrospective multi-center analysis does not permit
19 precise assessment of patient characteristics and homogeneous single-center preferences in
20 perioperative management, despite enrolling departments having similar behaviors in cases of
21 asymptomatic carotid stenosis management and CEA. Furthermore, the number of enrolled
22 patients it is slightly low to acquire robust evidence, even though the results are interesting and
23 reach statistical significance in some cases. Lastly, the long-term survival of our cohort is higher

1 than those described in other selected RSSs. This could be due to patient selection criteria, low
2 postprocedural stroke rate or other unknown variables. In addition, the relatively low number of
3 patients who died during follow-up may have affected the results, as well as the modest number
4 of in the baseline patients' cohort may influence interpretation of results, particularly in scoring
5 RSS performance. However, this was an analysis starting from real-life experience, to test RSSs'
6 applicability and validity, so differences in postoperative follow-up data, due to different
7 regional outcomes, make the results more convincing in our opinion.

8

9 **CONCLUSION**

10 Utilizing a multicenter, real-world population, we found two of six long-term RSSs, with some
11 limitations, may be used in predicting if asymptomatic patients will be sufficiently long-lived to
12 benefit from CEA, particularly for low-risk patients. However, RSSs have several limitations and
13 do not include prognostic information based upon plaque characteristics. For this reason, their
14 use alone generates only a partial patient assessment, which should be complemented with
15 inclusion of other features and parameters.

16

17 **DISCLOSURES:** None

18

19 **ACKNOWLEDGMENTS:** Authors would like to thank Mr. Edward Kiegle for his revision
20 of English grammar and syntax.

1 REFERENCES

- 2 1. Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A et al. Editor's Choice -
3 Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice
4 Guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg.*
5 2018;55(1):3-81.
- 6 2. Ricotta JJ, Aburahma A, Ascher E, Eskandari M, Faries P, Lal BK. Updated Society for
7 Vascular Surgery guidelines for management of extracranial carotid disease [published
8 correction appears in *J Vasc Surg.* 2012 Mar;55(3):894]. *J Vasc Surg.* 2011;54(3):e1-e31.
- 9 3. Paraskevas KI, Veith FJ, AbuRahma AF, Ascher E, Ricco JB. A comparison of the Society for
10 Vascular Surgery and the European Society for Vascular Surgery guidelines to identify which
11 asymptomatic carotid patients should be offered a carotid endarterectomy. *J Vasc Surg.*
12 2020;72(6):2149-2152.
- 13 4. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke
14 associated with asymptomatic severe carotid stenosis: results of a systematic review and
15 analysis. *Stroke.* 2009;40:e573-83.
- 16 5. Bissacco D, Barbeta I. Carotid endarterectomy: a world of discrepancies. *J Cardiovasc Surg*
17 (Torino). 2018;59(2):296-297.
- 18 6. Naylor AR, Schroeder TV, Sillesen H. Clinical and imaging features associated with an
19 increased risk of late stroke in patients with asymptomatic carotid disease. *Eur J Vasc Endovasc*
20 *Surg.* 2014;48(6):633-640.
- 21 7. Naylor AR, Sillesen H, Schroeder TV. Clinical and imaging features associated with an
22 increased risk of early and late stroke in patients with symptomatic carotid disease. *Eur J Vasc*
23 *Endovasc Surg.* 2015;49(5):513-523.

- 1 8. Bissacco D, Barbetta I, Carmo M. Risk Scoring Systems to Predict Long-Term Mortality After
2 Carotid Endarterectomy in Asymptomatic Patients: A Systematic Review. *Vasc Endovascular*
3 *Surg.* 2020;54(3):247-253.
- 4 9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for
5 systematic reviews and meta-analyses: the PRISMA statement. *BMJ.* 2009;339:b2535. Published
6 2009 Jul 21.
- 7 11. Setacci C, Argentero A, Cremonesi A, de Donato G, Galzerano G, Lanza G et al. Guidelines
8 on the diagnosis and treatment of extracranial carotid artery stenosis from the Italian Society for
9 Vascular and Endovascular Surgery. *J Cardiovasc Surg (Torino).* 2014;55(1):119-131.
- 10 12. Alcocer F, Mujib M, Lowman B, Patterson MA, Passman MA, Matthews TC et al. Risk
11 scoring system to predict 3-year survival in patients treated for asymptomatic carotid stenosis. *J*
12 *Vasc Surg.* 2013;57(6):1576-1580.
- 13 13. Conrad MF, Kang J, Mukhopadhyay S, Patel VI, LaMuraglia GM, Cambria RP. A risk
14 prediction model for determining appropriateness of CEA in patients with asymptomatic carotid
15 artery stenosis. *Ann Surg.* 2013;258(4):534-538.
- 16 14. Wallaert JB, Cronenwett JL, Bertges DJ, Schanzer A, Nolan BW, De Martino R et al.
17 Optimal selection of asymptomatic patients for carotid endarterectomy based on predicted 5-year
18 survival. *J Vasc Surg.* 2013;58(1):112-118.
- 19 15. Morales-Gisbert SM, Zaragoza García JM, Plaza Martínez Á, Gómez Palonés FJ, Ortiz-
20 Monzón E.. Development of an individualized scoring system to predict mid-term survival after
21 carotid endarterectomy. *J Cardiovasc Surg (Torino).* 2017;58(4):535-542.

- 1 16. Carmo M, Barbetta I, Bissacco D, Trimarchi S, Catanese V, Bonzini M et al. Development
2 and validation of a score to predict life expectancy after carotid endarterectomy in asymptomatic
3 patients. *J Vasc Surg.* 2018;67(1):175-182.
- 4 17. Keyhani S, Madden E, Cheng EM, Bravata DM, Halm E, Austin PC et al. Risk Prediction
5 Tools to Improve Patient Selection for Carotid Endarterectomy Among Patients With
6 Asymptomatic Carotid Stenosis. *JAMA Surg.* 2019 Apr 1;154(4):336-344.
- 7 18. Nguyen LL, Conte MS, Reed AB, Belkin M. Carotid endarterectomy: who is the high-risk
8 patient? *Semin Vasc Surg.* 2004;17(3):219-223.
- 9 19. Gasparis AP, Ricotta L, Cuadra SA, Char DJ, Purtil WA, Van Bemmelen PS et al. High-risk
10 carotid endarterectomy: fact or fiction. *J Vasc Surg.* 2003;37(1):40-46.
- 11 20. Howard DPJ, Gaziano L, Rothwell PM; Oxford Vascular Study. Risk of stroke in relation to
12 degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review,
13 and meta-analysis [published correction appears in *Lancet Neurol.* 2021 May;20(5):e4]. *Lancet*
14 *Neurol.* 2021;20(3):193-202.
- 15 21. Naylor AR, Gaines PA, Rothwell PM. Who benefits most from intervention for
16 asymptomatic carotid stenosis: patients or professionals? *Eur J Vasc Endovasc Surg.*
17 2009;37(6):625-632.
- 18 22. Paraskevas KI, Spence JD, Veith FJ, Nicolaides AN. Identifying which patients with
19 asymptomatic carotid stenosis could benefit from intervention. *Stroke.* 2014;45(12):3720-3724.
- 20 23. Volkers EJ, Algra A, Kappelle LJ, Jansen O, Howard G, Hendrikse J et al. Prediction Models
21 for Clinical Outcome After a Carotid Revascularization Procedure. *Stroke.* 2018;49(8):1880-
22 1885.

- 1 24. Savardekar AR, Narayan V, Patra DP, Spetzler RF, Sun H. Timing of Carotid
2 Endarterectomy for Symptomatic Carotid Stenosis: A Snapshot of Current Trends and
3 Systematic Review of Literature on Changing Paradigm towards Early Surgery. *Neurosurgery*.
4 2019;85(2):E214-E225.
- 5 25. Calvillo-King L, Xuan L, Zhang S, Tuhim S, Halm EA. Predicting risk of perioperative
6 death and stroke after carotid endarterectomy in asymptomatic patients: derivation and validation
7 of a clinical risk score. *Stroke*. 2010;41(12):2786-2794.
- 8 26. Rao V, Liang P, Swerdlow N, Li C, Solomon Y, Wyers M et al. Contemporary outcomes
9 after carotid endarterectomy in high-risk anatomic and physiologic patients. *J Vasc Surg*.
10 2020;71(1):104-110.
- 11 27. Cui L, Han Y, Zhang S, Liu X, Zhang J. Safety of Stenting and Endarterectomy for
12 Asymptomatic Carotid Artery Stenosis: A Meta-Analysis of Randomised Controlled Trials. *Eur J*
13 *Vasc Endovasc Surg*. 2018;55(5):614-624.
- 14 28. Cole TS, Mezher AW, Catapano JS, Godzik J, Baranoski JF, Nakaji P et al. Nationwide
15 Trends in Carotid Endarterectomy and Carotid Artery Stenting in the Post-CREST Era. *Stroke*.
16 2020;51(2):579-587.
- 17 29. DeMartino RR, Brooke BS, Neal D, Beck AW, Conrad MF, Arya S et al. Development of a
18 validated model to predict 30-day stroke and 1-year survival after carotid endarterectomy for
19 asymptomatic stenosis using the Vascular Quality Initiative. *J Vasc Surg*. 2017;66(2):433-
20 444.e2.
- 21 30. Bissacco D, Carmo M, Barbetta I, Dallatana R, Settembrini PG. Medical Therapy Before
22 Carotid Endarterectomy: Changes Over a 13-Year Period and Comparison Between
23 Asymptomatic and Symptomatic Patients. *Angiology*. 2018;69(2):113-119.

- 1 31. Domanin M, Bissacco D, Le Van D, Vergara C. Computational fluid dynamic comparison
- 2 between patch-based and primary closure techniques after carotid endarterectomy. *J Vasc Surg.*
- 3 2018;67(3):887-897.
- 4 32. Bissacco D, Domanin M, Trimarchi S. Moving on unconventional research fields for carotid
- 5 endarterectomy in asymptomatic patients. *J Vasc Surg.* 2021;73(5):1834.

Journal Pre-proof

Table I. Items used in selected risk score systems.

Item \ Selected study	Lee et al, 2013	Chaturvedi, 2013	Wahlqvist, 2013	Gisbert ¹⁵ , 2014	Carino, 2018	Rejzmani ¹⁷ (4C), 2019
Age	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Sex				<input checked="" type="checkbox"/>		
Smoke, past or current			<input checked="" type="checkbox"/>			
Diabetes Mellitus	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Chronic Obstructive Pulmonary Disease	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Heart Disease History	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Ipsilateral Carotid Stenosis Grade				<input checked="" type="checkbox"/>		
Antiplatelet Drugs				<input checked="" type="checkbox"/>		
Renal Status	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Statin Therapy		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/>	
Neck Radiation		<input checked="" type="checkbox"/>				
Congestive Heart Failure			<input checked="" type="checkbox"/>			<input checked="" type="checkbox"/>
Contralateral Carotid Stenosis Grade			<input checked="" type="checkbox"/>			
Cancer History						<input checked="" type="checkbox"/>

Table II. Demographic characteristics.

Characteristic	N (%) or $\mu \pm DS$
Age	73.1 \pm 8.8
Male	528 (64.0)
BMI	26.8 \pm 3.8
Smoke	290 (35.1)
Diabetes Mellitus	265 (32.1)
Chronic Obstructive Pulmonary Disease	143 (17.3)
Heart Disease History	245 (29.7)
Ipsilateral Carotid Stenosis Grade (%)	81.1 \pm 7.3
Antiplatelet Drugs	688 (83.4)
Preoperative Creatinine (mg/dL)	0.97 \pm 2.9
Statin Therapy	602 (72.9)
Neck Radiation	1 (0.1)
Congestive Heart Failure (NYHA class III/IV)	64 (7.7)
Contralateral Carotid Stenosis Grade (%)	38.3 \pm 18.7
Cancer History	88 (10.6)
General anesthesia	265 (32.1)
Arteriotomy technique	
primary closure	73 (8.8)
patch	29 (3.6)
eversion	723 (87.6)
Postoperative death	1 (0.1)
Combined postoperative stroke + TIA rate	16 (2.0)

NYHA: New York Heart Association classification; TIA: transient ischemic attack

Table III. Three-year risk scoring systems performance, according to original risk class division. PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio; HCv, Harrell's C value

Paper	Score class	Se	Sp	PPV	NPV	HR	CI	HCv	P
Alcocer ¹²	≤ 2	57.8	66.1	20.6	91.1	1	Reference	.638	<.001
	> 2					3.16	1.72 – 5.81		
Conrad ¹³	≤ 5	4.6	98.3	29.4	87.1	1	Reference	.567	.281
	6 – 8					0.81	0.39 – 1.67		
	9 – 11					0.80	0.32 – 2.02		
	12 – 14					1.46	0.58 – 3.69		
	≥ 15					3.62	1.07 – 12.3		
Wallaert ¹⁴	Low risk	31.6	75.5	19.1	85.8	1	Reference	.614	.034
	Medium risk					2.71	0.63 – 11.69		
	High risk					4.94	1.12 – 21.75		
Morales ¹⁵	< 4	29.5	71.9	14.5	86.3	1	Reference	.561	.613
	4 – 7*					0.62	0.23 – 1.65		
	8 – 10					1.15	0.47 – 2.83		
	> 10					0.87	0.35 – 2.14		
Carmo ¹⁶	0 – 3	13.7	83.2	11.1	86.4	1	Reference	.534	.591
	4 – 7					0.67	0.29 – 1.51		
	8 – 11					0.86	0.38 – 1.96		
	≥ 12					<i>null</i>	<i>null</i>		
Keyhani ¹⁷	0	0	99.7	0	86.7	1	Reference	.646	.002
	1					2.28	1.06 – 4.90		
	2					5.58	2.35 – 13.25		
	3 – 4					<i>null</i>	<i>null</i>		

* correct by Authors (originally overlapping classes)


Null: no patients in this risk class

Table IV. Five-year risk scoring systems performance, according to original risk class division. PPV, positive predictive value; NPV, negative predictive value; Se, sensitivity; Sp, specificity; HR, hazard ratio; CI, confidence interval; HCv, hazard class value; P, p-value.

Paper	Score class	Se	Sp	PPV	NPV	HR	CI	HCv	P
Alcocer ¹²	≤ 2	57.8	66.6	20.6	91.1	1	Reference	.595	.001
	> 2					2.06	1.33 – 3.20		
Conrad ¹³	≤ 5	4.6	98.3	29.4	87.1	1	Reference	.531	.793
	6 – 8					1.23	0.73 – 2.09		
	9 – 11					1.04	0.54 – 2.03		
	12 – 14					1.16	0.52 – 2.55		
	≥ 15					2.13	0.64 – 7.03		
Wallaert ¹⁴	Low risk	31.6	75.5	19.1	85.8	1	Reference	.599	.021
	Medium risk					1.76	0.73 – 4.22		
	High risk					3.05	1.24 – 7.50		
Morales ¹⁵	< 4	29.5	71.9	14.5	86.3	1	Reference	.557	.414
	4 – 7*					0.68	0.33 – 1.41		
	8 – 10					1.21	0.62 – 2.39		
	> 10					0.96	0.49 – 1.87		
Carmo ¹⁶	0 – 3	13.8	83.2	11.1	86.4	1	Reference	.521	.737
	4 – 7					0.89	0.51 – 1.54		
	8 – 11					0.79	0.42 – 1.49		
	≥ 12					<i>null</i>	<i>null</i>		
Keyhani ¹⁷	0	0	99.72	0	86.8	1	Reference	.609	<.001
	1					1.56	0.94 – 2.61		
	2					3.53	1.92 – 6.51		
	3 – 4					<i>null</i>	<i>null</i>		

* correct by Authors (originally overlapping classes)

null: no study population patients in this risk class



1 **Figure legend**

2 **Figure 1.** Search process flow chart according to PRISMA guidelines. CV: cardiovascular; CAS:

3 carotid artery stenting; RSS: risk scoring system

4

Journal Pre-proof

Supplementary material of the paper “**ROLE OF RISK SCORING SYSTEMS IN PREDICTING LIFE EXPECTANCY AFTER CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS.**” By Bissacco et al.

S1. Search strategy for RSSs (technical details).

Similar medical subject headings (MESH) or Embase subject headings (EMTREE) were used and combined (“carotid endarterectomy”, “survival analysis”, “risk factors”, “mortality”, “follow up” and “follow-up studies”). Terms not included in the Mesh/EMTREE indexes were also used (“risk scoring system”, “score” and “carotid score”). To connect terms, Boolean operators “AND” and/or “OR” were used. Furthermore, articles not already indexed (ahead of print or on-line first) were searched in vascular journal websites, to include the following peer-reviewed journals: Journal of Vascular Surgery, Annals of Vascular Surgery, European Journal of Endovascular and Vascular Surgery, Vascular, Stroke, Vascular Medicine, Angiology and Circulation (search on October 30, 2020).

S2. Supplementary tables

Table Is. Selected papers.

Author, year	Country	Study period	Study design	Type of Patients	Primary endpoints	Validation
<i>Alcocer</i> ¹² , 2013	USA	1999 - 2008	Retrospective, single center	Asx	3y survival	VC = Sx patients
<i>Morales</i> ¹³ , 2014	ESP	1997 - 2010	Retrospective, single center	Asx + Sx	3y survival	Not validated
<i>Conrad</i> ¹⁴ , 2013	USA	1989 - 2005	Retrospective, single center	Asx	30d stroke/death 5y survival	C-statistics Hosmer-Lemeshow test Internal
<i>Wallaert</i> ¹⁵ , 2013	USA	2003 - 2011	Retrospective, multicentric (VSGNE registry)	Asx	5y survival	Internal
<i>Carmo</i> ¹⁶ , 2018	ITA	2002 - 2013	Retrospective, multicentric	Asx	30d stroke/death 5y survival	DC + VC
<i>Keyhani</i> ¹⁷ , 2020	USA	2005-2009	Retrospective, multicentric (VA registry)	Asx	5y survival	Internal

Sx, symptomatic; Asx, asymptomatic; DC, derivation cohort; VC, validation cohort; VSGNE, Vascular Study Group of New England; VA, Veterans Affairs.


Table IIs. Selected risk scoring system and present study population postoperative outcomes.

Author, year	No. of Patients	FU period (months)	30-d stroke rate	30-d survival rate	3-y survival rate	3-y stroke free survival rate	5-y survival rate
Alcocer ¹² , 2013	506*	36	2.2	99.1	86.2	97.4	-
Morales ¹³ , 2014	453†	53.4	2.9	99.3 (99.2 Sx, 99.5 Asx)	88.4 (86.2 Sx, 90.5 Asx)	98.8 (99.0 Sx, 97.8 Asx)	62.1 (51.0 Sx, 69.7 Asx)
Conrad ¹⁴ , 2013	1791	130±49	1.1	99.3	-	-	73
Wallaert ¹⁵ , 2013	4114	60	0.6	99.6	-	-	82
Carmo ¹⁶ , 2018	1015	64.6±34.7	-	99.8	92	-	85
Keyhani ¹⁷ , 2020	2325	40	2.3	99.3	-	-	70.5
Bissacco, 2021	825	61.9±22.9	1.4	99.8	94.5	-	90.3

Sx, symptomatic; Asx, asymptomatic. * 427 carotid endarterectomy and 79 carotid angioplasty and stenting; † 221 asymptomatic and 222 symptomatic patients.

S3. Likert Scale definition

Figure 1s. A 5-range Likert Scale was proposed for each item to objectively quantify the RSS reproducibility in our real-world non-selected patient population.



In particular, “very poor applicability” was associated with score 1, while “very good applicability” with score 5. The average score resulting from Authors’ responses was used to quantify item reproducibility in our study population.

S4. Items definitions and consensus

For each RSS, three Authors representative for each participating center (DB, CM and JM) were interrogated through the Likert Scale for each item.

Furthermore, after Likert Scale completion, all Authors took part in item definition.

A univocal definition derived from Authors' agreement was then proposed, in order to better consider in a univocal way each variable, and to avoid mismatch during dataset building and validation analysis.

Results of Likert Scale analysis and final definition was achieved, as describe in Table III:


Item	Likert Scale mean score	Used in n/6 RSSs	Comment	Definition*
Age	5	5	None	Age of patient at surgery
Sex	5	1	None	Sex (Gender) of patient at birth
Smoke History	3.3	1	Used as current, past or current + past smoking	Smoking history (past or current)
Diabetes Mellitus	4.7	5	None	Medication or confirmed diagnosis at surgery
Chronic Obstructive Pulmonary Disease	4.7	5	None	Medication or confirmed diagnosis at surgery
Heart disease history	3.7	4	Defined as coronary artery intervention, coronary artery disease (past, current?), ischemic heart disease (past, current?)	Coronary artery disease history (past, treated or present, both asymptomatic and symptomatic)
Any cancer disease	5	1	None	Any cancer in the past 5 years
Ipsilateral stenosis grade	5	1	None	Ipsilateral stenosis grade >90%
Antiplatelet drugs	4.7	1	Irrespective of the type of drugs (aspirin, clopidogrel, ...) and number (dual antiplatelet therapy)	Any antiplatelet drugs intake before treatment
Renal function	1.7	5	Define using Creatinine, estimated Glomerular Filtration Rate calculated with different	Any type of renal insufficiency, define as creatinine \geq 1.5 mg/dL or an estimated glomerular filtration

			equation used, Dialysis	rate \leq 30 (any equation) or dialysis therapy
Not on statin therapy	5	3		Not on statin therapy at the time of surgery
Neck radiation	5	1	None	Any type of previous radiation therapy
Contralateral carotid stenosis	4.7	1	No NASCET or ECST measurement methods mentioned	Contralateral carotid stenosis >50%
Congestive heart failure	2.6	2	No other specific information mentioned (Grade? Past or present?)	Congestive heart failure at the time of surgery

* According to RSSs definitions reported and Author consensus achieved

S5. Kaplan Meyer analysis

Figure 2s. Kaplan Meyer analysis on postoperative survival rate.



	Years										
	0	1	2	3	4	5	6	7	8	9	10
Number at risk	825	801	786	723	655	307	163	91	69	55	18
Cumulative number of events	0	23	37	45	60	80	94	99	102	107	109
Cumulative number of censoring	0	1	2	57	113	438	568	635	654	663	698